









Drug and Biologic Coverage Criteria

HCPCS CODE	DESCRIPTION
J1302	Injection, sutimlimab-jome, 10 mg

**AVAILABLE DOSAGE FORMS:**

Enjymo SOLN 1100MG/22MLsingle-dose vial

**REFERENCES**

1. Enjymo (sutimlimab) [prescribing information]. Waltham, MA: Bioverativ USA Inc; March 2023.
2. Berentsen S. How I treat cold agglutinin disease. *Blood* 2021; 137:1295.
3. Röth A, Barcellini W, D'Sa S, et al. Sutimlimab in Cold Agglutinin Disease. *N Engl J Med* 2021; 384:1323.
4. Berentsen S, Tjønnfjord GE. Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. *Blood Rev* 2012; 26:107.
5. Schöllkopf C, Kjeldsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. *Leuk Lymphoma* 2006; 47:253.
6. Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. *Blood* 2004; 103:2525.
7. Gueli A, Gottardi D, Hu H, et al. Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case report. *Blood Transfus* 2013; 11:311.
8. Fattizzo B, Zaninoni A, Pettine L, et al. Low-dose rituximab in autoimmune hemolytic anemia: 10 years after. *Blood* 2019; 133:996.
9. Berentsen S, Randen U, Oksman M, et al. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. *Blood* 2017; 130:537.

SUMMARY OF REVIEW/REVISIONS	DATE
REVISION- Notable revisions: Required Medical Information Continuation of Therapy Place of Administration FDA-Approved Uses References	Q1 2024
REVISION- Notable revisions: Required Medical Information Continuation of Therapy Route of Administration Coding/Billing Information	Q1 2023
NEW DEVELOPMENT	Q2 2022